On this page
Key takeaways
• Fisetin is a senolytic — it clears senescent cells. Spermidine is an autophagy inducer — it helps healthy cells recycle damaged components (1,2).
• Spermidine has stronger epidemiological evidence for all-cause mortality reduction, from a large prospective population study (3).
• Spermidine has RCT evidence for cognitive improvement in older adults at risk for dementia (4). Fisetin’s equivalent RCT (AFFIRM) is unreported (7).
• The mechanisms are complementary, not overlapping — senolytic clearance addresses accumulated dysfunction; autophagy induction addresses ongoing cellular maintenance.
• Both are commonly stacked in longevity practice without documented adverse interactions.
• Spermidine’s bioavailability picture is complicated by homeostatic regulation — the Keohane 2024 crossover trial suggested that supplemental spermidine may not meaningfully raise circulating polyamine levels (6).
Quick answer
Fisetin and spermidine target different hallmarks of ageing through different mechanisms. Fisetin is a senolytic — it selectively kills senescent cells that accumulate in tissue with age (1). Spermidine is an autophagy inducer — it supports the intracellular recycling of damaged proteins and organelles in healthy cells (2). Spermidine has the stronger current human evidence: a large prospective population study associates higher spermidine intake with lower all-cause mortality (3), and a small RCT reported cognitive benefits in older adults (4). Fisetin’s human evidence is largely still pending. The mechanisms are complementary rather than overlapping, and combining them is a defensible and common approach in longevity practice. For the full clinical context on fisetin, see our complete clinician’s guide.
Different mechanisms — the fundamental distinction
The most important thing to understand about the fisetin vs spermidine comparison is that these are two different pharmacological classes targeting two different hallmarks of ageing.
Fisetin — senolytic clearance
Fisetin’s primary identity is senolytic. Senescent cells — cells that stopped dividing but did not die on schedule — accumulate in tissue over decades and secrete inflammatory factors that damage the surrounding tissue. Fisetin briefly pushes senescent cells past their apoptotic threshold, clearing them and reducing downstream inflammation. This is a subtractive intervention: fewer bad cells.
Spermidine — autophagy induction
Spermidine’s primary identity is as an autophagy inducer. Autophagy — the cellular process of packaging damaged proteins, organelles, and other cellular debris into autophagosomes for lysosomal degradation — declines with age and its restoration is a leading candidate mechanism for longevity intervention. Spermidine induces autophagy via inhibition of the acetyltransferase EP300, indirectly disinhibiting the autophagic machinery (2). This is a maintenance intervention: better housekeeping in existing cells.
These mechanisms are not competing hypotheses — they are addressing different aspects of the ageing process. Senolytic clearance without concurrent autophagy support leaves the remaining cells vulnerable to the same damage that made others senescent. Autophagy induction without senolytic clearance means senescent cells persist and continue producing SASP factors. A biology-informed longevity stack could reasonably include both.
Human evidence — spermidine’s current lead
Spermidine has a more mature human evidence base than fisetin, though neither has a fully published Phase 3 outcome trial.
The Bruneck study — spermidine and mortality
Kiechl and colleagues (Am J Clin Nutr, 2018) reported a prospective population-based analysis of the Bruneck cohort in Northern Italy, tracking approximately 800 adults over 20 years (3). Participants in the highest tertile of dietary spermidine intake had significantly lower all-cause mortality than those in the lowest tertile. The magnitude was substantial — the mortality reduction was comparable to what dietary Mediterranean-style patterns produce in similar cohorts.
This is an observational study and subject to confounding by overall diet quality. But it is a genuine longitudinal outcome study — fisetin has no equivalent. If your goal is to bet on a longevity-relevant supplement with existing human outcome evidence, spermidine has the strongest case.
The Wirth cognitive trial
Wirth and colleagues (Cortex, 2018) randomised 30 older adults at risk for dementia to spermidine supplementation vs placebo for three months and reported modest cognitive improvements on memory tasks (4). The trial was small and short but represents the first RCT-level cognitive evidence for spermidine. Follow-up trials (SmartAge, others) are ongoing (5).
The Keohane 2024 bioavailability question
A more recent and complicating result. Keohane and colleagues (2024) ran a randomised crossover trial of oral spermidine supplementation and measured circulating polyamine concentrations (6). The supplemental spermidine did not meaningfully raise serum polyamine levels above dietary intake baseline — suggesting homeostatic regulation that limits how much supplemental spermidine actually reaches circulation. This is a caveat worth understanding: mechanistic reasoning that assumes supplemental spermidine acts on tissue like injected spermidine may be optimistic. The Bruneck mortality data reflect dietary polyamine intake in the context of whole foods, not necessarily what a spermidine capsule delivers.
Fisetin’s human evidence
Fisetin’s equivalent human evidence is largely pending. The AFFIRM trial (NCT03430037) is the Phase 2 test of pulsed fisetin against frailty in older women; it has been unreported since 2018 (7). The Krishnakumar 2022 study demonstrated poor bioavailability of unformulated fisetin (8). See our dedicated senolytic article for the full evidence review.
Bioavailability and dosing comparison
|
Aspect |
Fisetin |
Spermidine |
|
Mechanism |
Senolytic |
Autophagy inducer |
|
Typical daily dose |
100–500 mg (continuous) or 20 mg/kg pulsed |
1–10 mg |
|
Dietary sources |
Strawberries, apples, persimmons |
Wheat germ, aged cheese, natto |
|
Bioavailability caveat |
Poor absorption, low plasma peaks |
Homeostatic regulation, unclear if it raises circulating polyamines |
|
Peer-reviewed human RCT |
None yet published |
One small cognitive trial (4) |
|
Epidemiological mortality data |
Absent |
Bruneck cohort (3) |
Note the dose difference: fisetin at hundreds of milligrams, spermidine at single-digit milligrams. This reflects different pharmacology — spermidine is an endogenous polyamine present in the body at millimolar concentrations in some tissues, and supplementation is intended to modestly boost intake rather than deliver a pharmacological dose.
The stacking case
Combining fisetin and spermidine in a longevity supplement stack is a common and defensible practice. The theoretical rationale is mechanistically strong: two different hallmarks of ageing, targeted independently, with no known negative interaction. Neither compound competes for the same absorption pathway. Neither shares meaningful CYP-mediated metabolism (spermidine is metabolised by polyamine oxidases, not cytochromes P450).
Practical stacking: spermidine at 1–10 mg daily with breakfast (continuous); fisetin at either 100–500 mg daily with the same meal (continuous flavonoid supplementation) or at the 20 mg/kg pulsed dose on two consecutive days per month (senolytic protocol). Both benefit from fat co-ingestion. Both can be taken alongside NMN, urolithin A, or other longevity supplements without documented interaction. See our how and when to take fisetin article for the practical guidance.
When to choose one over both
Some readers ask which to prioritise if budget or supplement burden is a constraint. The answer depends on what you are betting on.
If you are betting on existing human outcome data: spermidine has the stronger case (Bruneck epidemiology, small cognitive RCT).
If you are betting on strong preclinical senolytic biology and pending trial validation: fisetin has the more specific mechanistic case.
If you are older, frail, or have visible ageing markers you want to slow: the senolytic bet (fisetin) targets accumulated damage; the autophagy bet (spermidine) targets ongoing maintenance. Both are relevant.
If cognitive endpoints matter most to you: the small Wirth RCT gives spermidine a modest edge in current evidence (4).
What we still don't know
• Whether combining fisetin and spermidine produces additive human benefit on any endpoint. Not tested.
• Whether supplemental spermidine meaningfully raises tissue polyamine levels given the Keohane 2024 homeostatic finding (6).
• Whether the Bruneck mortality-benefit signal from dietary spermidine translates to capsule supplementation. The trial-level evidence is limited.
• Whether one or both compounds should be pulsed rather than continuous. Pulsed senolytic makes biological sense for fisetin; continuous is the default for spermidine because autophagy induction is a maintenance function.
Bottom line
Fisetin and spermidine are different pharmacological classes targeting different hallmarks of ageing. Spermidine has the stronger human evidence today — a large prospective mortality study and a small RCT showing cognitive benefit. Fisetin has the stronger preclinical senolytic biology, with human trial validation still pending. The mechanisms are complementary and combining the two is a common longevity practice with no known negative interaction. Choose spermidine if you want the currently-most-supported human evidence; choose fisetin if you want to bet on the specific senolytic hypothesis; take both if the combined cost and supplement burden is acceptable. For the broader fisetin context, see our complete clinician’s guide.
Frequently asked questions
Is spermidine or fisetin better for longevity?
Neither is proven to extend human lifespan. Spermidine has better observational mortality data (Bruneck cohort). Fisetin has stronger preclinical senolytic activity. Both are reasonable bets on different mechanisms.
Can I take fisetin and spermidine together?
Yes. No known interaction. Same meal is fine. Both benefit from co-ingestion with fat.
Which has more evidence in humans?
Spermidine. The Bruneck cohort mortality data and Wirth cognitive RCT together give it more human data than fisetin currently has.
Is spermidine safer than fisetin?
Both have favourable safety profiles at supplemental doses. Spermidine is an endogenous molecule and dietary intake at high levels (aged cheeses, wheat germ) is unremarkable. Fisetin’s long-term safety data are less mature but no serious concerns have emerged.
Which is cheaper?
Spermidine capsules typically cost less per month than fisetin capsules because the daily dose is much smaller (single-digit milligrams vs hundreds of milligrams).
Do fisetin and spermidine cancel each other out?
No. The mechanisms are complementary — fisetin removes senescent cells; spermidine supports healthy cell maintenance.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. Eisenberg T, Abdellatif M, Schroeder S, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med. 2016;22(12):1428-1438. https://pubmed.ncbi.nlm.nih.gov/27841876/
3. Kiechl S, Pechlaner R, Willeit P, et al. Higher spermidine intake is linked to lower mortality: a prospective population-based study. Am J Clin Nutr. 2018;108(2):371-380. https://pubmed.ncbi.nlm.nih.gov/29955838/
4. Wirth M, Benson G, Schwarz C, et al. The effect of spermidine on memory performance in older adults at risk for dementia: a randomized controlled trial. Cortex. 2018;109:181-188. https://pubmed.ncbi.nlm.nih.gov/30388439/
5. Schwarz C, Horn N, Benson G, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge) — study protocol for a randomized controlled trial. Alzheimers Res Ther. 2022;14:12. https://pubmed.ncbi.nlm.nih.gov/35063014/
6. Keohane K, Sanchez FA, Miller LM, et al. Effects of spermidine supplementation on serum polyamine concentrations in healthy adults: a randomised, controlled, crossover trial. Br J Nutr. 2024;132(4):474-485. https://pubmed.ncbi.nlm.nih.gov/39238100/
7. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037
8. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72